Why Partner with CSL?
Innovation has been in our DNA for more than a century. We have the full spectrum of strengths from research and clinical development to manufacturing and commercialization in immunology, novel biologics, and vaccines. We know that partnerships can accelerate innovation and delivery of new life-saving and protective medicines and we work closely with organizations outside our walls that have unique technologies to address our patients’ unmet needs around the globe.
CSL is a fully integrated biotechnology company with global manufacturing and commercial operations for recombinant proteins, vaccines, biologics, and plasma therapeutics with hubs in the US, EU, Australia and Asia. Our fiscal year 2016-2017 revenue is over $6.9 billion and we have a global presence in more than 60 countries.
Our Partnering Approach
Our approach is to collaborate with industry, academia or other groups developing great products and technologies that have the capacity to address unmet medical need. We will work to find mutually beneficial arrangements that include traditional licensing, joint ventures, strategic investments or other suitable structures that most effectively leverage our combined capabilities.
We are particularly interested in products and technologies that can have an immediate impact as well as clinical, or pre-clinical, technologies that can address significant unmet need in our areas of interest: immunology, hematology and thrombosis, transplant, neurology, cardiovascular and metabolic disease, respiratory and critical care.
Seqirus is CSL’s influenza vaccines business. To learn more about their partnering approach, please visit Seqirus.com.